Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis

Clinical Immunology

Volumn 150, Issue 1, 2014, Pages 109-120

  Saresella, Marina ^a   Gatti, Andrea ^a   Tortorella, Paola ^a   Marventano, Ivana ^a   Piancone, Federica ^a   La Rosa, Francesca ^a   Caputo, Domenico ^a   Rovaris, Marco ^a   Biasin, Mara ^b   Clerici, Mario ^a,b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Multiple sclerosis; Neuroinflammation; Signal transduction; TLR3; Toll like receptors

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD14 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; MOSAICISM; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

MULTIPLE SCLEROSIS; NEUROINFLAMMATION; SIGNAL TRANSDUCTION; TLR3; TOLL LIKE RECEPTORS;

ADULT; CELLS, CULTURED; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; POLY I-C; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84890279714     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.10.012     Document Type: Article

References (39)

1. Ferrante P., Fusi M.L., Saresella M., Caputo D., Biasin M., Trabattoni D., Salvaggio A., Clerici E., de Vries J.E., Aversa G., Cazzullo C.L., Clerici M. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J. Immunol. 1998, 160:1514-1521.
2. Clerici M., Saresella M., Trabattoni D., Speciale L., Fossati S., Ruzzante S., Cavaretta R., Filippi M., Caputo D., Ferrante P. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J. Neuroimmunol. 2001, 121:88-101.
3. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
4. Chastain E.M., Miller S.D. Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunol. Rev. 2012, 245:227-238.
5. Nylander A., Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2012, 122:1180-1188.
6. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 2003, 3:984-993.
7. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
8. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
9. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
10. den Dunnen J., Vogelpoel L.T., Wypych T., Muller F.J., de Boer L., Kuijpers T.W., Zaat S.A., Kapsenberg M.L., de Jong E.C. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcγRIIa in human dendritic cells. Blood 2012, 120:112-121.
11. Cook D.N., Pisetsky D.S., Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 2004, 5:975-979.
12. Drexler S.K., Foxwell B.M. The role of toll-like receptors in chronic inflammation. Int. J. Biochem. Cell Biol. 2010, 42:506-518.
13. Okun E., Griffioen K.J., Lathia J.D., Tang S.C., Mattson M.P., Arumugam T.V. Toll-like receptors in neurodegeneration. Brain Res. Rev. 2009, 59:278-292.
14. Racke M.K., Drew P.D. Toll-like receptors in multiple sclerosis. Curr. Top. Microbiol. Immunol. 2009, 336:155-168.
15. Rolland E., Jouvin-Marche C., Viret M., Faure H., Perron P.N. Marche, The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J. Immunol. 2006, 176:7636-7644.
16. Okun E., Griffioen K.J., Mattson M.P. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 2011, 34:269-281.
17. Gambuzza M., Licata N., Palella E., Celi D., Foti Cuzzola V., Italiano D., Marino S., Bramant P. Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management. J. Neuroimmunol. 2011, 239:1-12.
18. Ruggiero V. Involvement of IL-1R/TLR signalling in experimental autoimmune encephalomyelitis and multiple sclerosis. Curr. Mol. Med. 2012, 12:218-236.
19. Marta M., Andersson A., Isaksson M., Kämpe O., Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2008, 38:565-575.
20. Touil T., Fitzgerald D., Zhang G.X., Rostami A., Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-β. J. Immunol. 2006, 177:7505-7509.
21. O'Neill L.A. 'Fine tuning' TLR signaling. Nat. Immunol. 2008, 9:459-461.
22. Christophi G.P., Hudson C.A., Gruber R.C., Christophi C.P., Mihai C., Mejico L.J., Jubelt B., Massa P.T. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab. Invest. 2008, 88:243-255.
23. Christophi G.P., Panos M., Hudson C.A., Christophi R.L., Gruber R.C., Mersich A.T., Blystone S.D., Jubelt B., Massa P.T. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab. Invest. 2009, 89:742-759.
24. Boonstra, Rajsbaum R., Holman M., Marques R., Asselin-Paturel C., Pereira J.P., Bates E.E., Akira S., Vieira P., Liu Y.T., Trinchieri G., O'Garra A. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 2006, 177:7551-7558.
25. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., Piesche M., Schroers R., Weiss E., Kirschning C.J., Rochford C.D., Brück W., Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006, 116:456-464.
26. Biasin M., Piacentini L., Lo Caputo S., Naddeo V., Pierotti P., Borelli M., Trabattoni D., Mazzotta F., Shearer G.M., Clerici M. TLR activation pathways in HIV-1-exposed seronegative individuals. J. Immunol. 2010, 184:2710-2717.
27. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly (I:C). Adv. Drug Deliv. Rev. 2008, 60:805-812.
28. Kawai T., Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 2007, 13:460-469.
29. García M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 2006, 70:1032-1060.
30. Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat. Immunol. 2003, 4:161-167.
31. Dunn S.E., Ousman S.S., Sobel R.A., Zuniga L., Baranzini S.E., Youssef S., Crowell A., Loh J., Oksenberg J., Steinman L. Peroxisome proliferator-activated receptor (PPAR) alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J. Exp. Med. 2007, 204:321-330.
32. Carty M., Goodbody R., Schröder M., Stack J., Moynagh P.N., Bowie A.G. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 2006, 7:1074-1081.
33. Kondo T., Kawai T., Akira S. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol. 2012, 33:449-458.
34. Miranda-Hernandez S., Gerlach N., Fletcher J.M., Biros E., Mack M., Körner H., Baxter A.G. Role for MyD88, TLR2 and TLR9 but not TLR1, TLR4 or TLR6 in experimental autoimmune encephalomyelitis. J. Immunol. 2011, 187:791-804.
35. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
36. Tuller T., Atar S., Ruppin E., Gurevich M., Achiron A. Global map of physical interactions among differentially expressed genes in multiple sclerosis relapses and remissions. Hum. Mol. Genet. 2011, 20:3606-3619.
37. Gurevich M., Achiron A. The switch between relapse and remission in multiple sclerosis: continuous inflammatory response balanced by Th1 suppression and neurotrophic factors. J. Neuroimmunol. 2012, 252:83-88.
38. Achiron A., Feldman A., Magalashvili D., Dolev M., Gurevich M. Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis. PLoS One 2012, 7:e46871.
39. Hong J., Zang Y.C., Hutton G., Rivera V.M., Zhang J.Z. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J. Neuroimmunol. 2004, 152:126-139.